Antiparasitic Drugs Market Size & Growth Forecast 2026–2035, By Segments (Route of Administration, Distribution Channel, Drug Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Antiparasitic Drugs Market size was over USD 19.54 Billion in 2025 and is likely to grow at a 5.2% CAGR between 2026 and 2035, exceeding USD 32.44 Billion by 2035. The industry revenue for 2026 is assessed at USD 20.42 billion.

• Base Year Value (2025): USD 19.54 Billion
• CAGR (2026-2035): 5.2%
• Forecast Year Value (2035): USD 32.44 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Key Takeaways

• Asia Pacific region garnered around 43.3% market share in 2025, fueled by high prevalence of parasitic infections.
• Asia Pacific region will expand at over 6% CAGR through 2035, supported by improving healthcare access in emerging markets.
• Securing 58.8% of the market in 2025, oral segment was strengthened by patient preference for convenient, non-invasive treatments.
• The hospital pharmacies segment recorded 49.5% revenue share in 2025, impelled by dominance in dispensing for inpatient treatments.
• Achieving 41.2% share in 2025, anthelmintics segment maintained its lead, sustained by high prevalence of worm infections in developing regions.
• The top participants in the antiparasitic drugs market are Pfizer (USA), GlaxoSmithKline (UK), Merck (USA), Sanofi (France), Bayer (Germany), Novartis (Switzerland), Mylan (USA), Cipla (India), Zoetis (USA), Elanco (USA).

Market Growth Drivers and Industry Trends

Rising prevalence of parasitic infections increasing global demand for antiparasitic therapeutics

Higher incidence of parasitic infections is directly driving demand for the antiparasitic drugs market by increasing the volume of diagnosed cases that require both immediate treatment and broader control efforts. As infection burdens remain concentrated in settings with limited sanitation, vector exposure, and uneven healthcare access, public health systems, NGOs, and commercial suppliers are compelled to secure reliable supplies of antiparasitic therapeutics for routine care, outbreak response, and preventive treatment campaigns. This pattern strengthens market development by expanding procurement activity, widening use across primary and community care settings, and reinforcing the need for product availability in both established and underserved treatment channels.

Growing drug resistance driving development of next-generation antiparasitic treatment solutions

Drug resistance is reshaping purchasing and development decisions in the antiparasitic drugs market by reducing confidence in older therapies and increasing the value of products that can deliver improved efficacy against resistant strains. Manufacturers respond by prioritizing reformulations, combination therapies, and novel mechanisms of action, while healthcare providers and public health programs become more selective in treatment protocols to avoid repeated therapeutic failure. This dynamic supports market expansion by shifting investment toward differentiated pipelines and creating stronger adoption pathways for newer antiparasitic treatment solutions that address persistent resistance-related gaps in care.

Increasing global travel and migration expanding need for parasite infection management programs

Rising cross-border travel and migration are influencing market adoption in the antiparasitic drugs market by exposing more healthcare systems to imported parasitic infections that may be unfamiliar in routine clinical practice. Hospitals, travel medicine clinics, border health programs, and public agencies increasingly need screening, diagnosis-linked treatment access, and stock readiness for a wider range of parasite-related conditions. That practical requirement contributes to market size growth by broadening the geographic footprint of demand, not only in endemic regions but also in destination countries where case management capacity and treatment availability are becoming more important.

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the antiparasitic drugs market, backed by established pharmaceutical distribution networks, broad access to prescription therapies, and consistent diagnosis and treatment across hospitals, clinics, and retail pharmacy channels. The region’s leadership is strengthened by structured healthcare systems that enable timely parasite testing, physician-led treatment selection, and reliable product availability, which keeps demand concentrated in formal care settings. Ongoing use of branded and generic therapies across human health applications also helps sustain purchasing volumes and steady market activity.

Asia Pacific is projected to expand at a 5.88% CAGR over the forecast period in the antiparasitic drugs market, driven by rising treatment demand across densely populated countries where parasitic infections remain a persistent healthcare concern. Growth is being impelled by improving access to healthcare services, wider medicine availability through urban and semi-urban pharmacy networks, and expanding public health efforts focused on early detection and treatment coverage. As more patients enter organized care pathways and treatment access improves, prescription volumes and drug uptake continue to accelerate across the region.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

No card data available for this language/report.

Segment Leadership and Growth Trends

  Route of Administration Segment Analysis: Oral (Largest Segment) vs Topical (Fastest-Growing Segment)

Oral held the largest share of the antiparasitic drugs market in 2025, supported by its established role across a broad range of parasitic infections that require systemic treatment. its position is underpinned by routine prescribing familiarity, ease of administration in outpatient and institutional settings, and the practicality of oral dosing for conditions where whole-body drug exposure is needed rather than localized treatment. This combination keeps Oral route of administration central to treatment use patterns in the antiparasitic drugs market.

Topical is the fastest-growing route of administration in the antiparasitic drugs market as demand rises for targeted treatment approaches that act directly at the site of infestation or infection. Its momentum is tied to practical use advantages in cases where localized therapy can improve convenience and reduce the need for systemic exposure, making it an increasingly attractive option relative to oral alternatives for appropriate indications. Growth is also supported by patient preference for accessible, easy-to-apply treatments in everyday care settings.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail Pharmacies (Fastest-Growing Segment)

Hospital Pharmacies accounted for the largest share of the antiparasitic drugs market in 2025, reflecting their central role in dispensing treatments linked to physician-led diagnosis and supervised care pathways. Their position is reinforced by the need for controlled prescribing, treatment management in more acute or complex cases, and direct integration with hospital-based clinical decision-making. These practical care delivery patterns help Hospital Pharmacies maintain their leading share in the antiparasitic drugs market.

Retail Pharmacies are the fastest-growing distribution channel in the antiparasitic drugs market, driven by expanding patient reliance on convenient access points for prescription fulfillment and follow-up treatment needs. Their growth relative to hospital pharmacies is supported by everyday accessibility, broad community presence, and their fit with routine treatment journeys that do not require hospital-based dispensing. As more care shifts toward outpatient management where appropriate, Retail Pharmacies are gaining momentum as a practical channel for antiparasitic drug access.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Route of Administration	Oral, Injectable, Topical	Oral	Topical
Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies	Hospital Pharmacies	Retail Pharmacies
Drug Type	Anthelmintics, Antiprotozoals, Ectoparasiticides, Others	Anthelmintics	Antiprotozoals

Competitive Landscape and Market Positioning

Key companies in the antiparasitic drugs market:

1. GlaxoSmithKline plc (U.K.)

2. Merck KGaA (Germany)

3. Novartis AG (Switzerland)

4. Bayer AG (Germany)

5. F. Hoffmann-La Roche Ltd. (Switzerland)

6. Sanofi S.A. (France)

7. Cipla Limited (India)

8. Ipca Laboratories Limited (India)

9. Mankind Pharma Limited (India)

10. Zydus Lifesciences Limited (India)

The antiparasitic drugs market is witnessing ongoing development of advanced therapies and combination treatments aimed at improving treatment efficacy and addressing resistance concerns. Manufacturers are investing in research initiatives and regulatory approvals to expand therapeutic applications across human and veterinary healthcare. Growing focus on neglected tropical diseases and preventive healthcare programs is also contributing to market expansion.

Industry Development/News

Company Name	Date	Key Development
Appili Therapeutics	Apr-25	Achieved formal alignment with the U.S. FDA regarding New Drug Application requirements for ATI-1801, a novel topical paromomycin therapy. The regulatory clarity positions the company for an official product submission targeting the treatment of cutaneous leishmaniasis.
May & Baker Nigeria PLC	May-22	Introduced Artelum Combo, an innovative anti-malarial formulation combining Artemether, Lumefantrine, and Paracetamol into a single convenient dose. This medication addresses public health needs by providing a comprehensive single-package therapy option to effectively treat malaria nationwide.
Dr. Reddy’s Laboratories Ltd	Jul-21	Received regulatory approval from the U.S. FDA to commercialize generic hydroxychloroquine sulfate tablets for malaria treatment. This key approval directly enriched the pharmaceutical company's therapeutic product line, driving elevated international sales volumes and market presence.
Cipla	Sep-18	Secured final regulatory approval from the U.S. FDA for its generic version of Impax Laboratories' Albenza (Albendazole 200mg tablets). The launch enabled the firm to significantly widen its anti-infective drug portfolio and address a broader global patient demographic.